Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PM86 | ISIN: US0021202025 | Ticker-Symbol: 471A
Tradegate
28.03.24
19:18 Uhr
1,770 Euro
-0,080
-4,32 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ATYR PHARMA INC Chart 1 Jahr
5-Tage-Chart
ATYR PHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,7401,78019:20
1,7401,78019:20

Aktuelle News zur ATYR PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.03.aTyr Pharma Inc reports results for the quarter ended in December - Earnings Summary20
14.03.aTYR PHARMA INC - 10-K, Annual Report2
14.03.Recap: aTyr Pharma Q4 Earnings4
14.03.aTyr Pharma GAAP EPS of -$0.25 misses by $0.013
14.03.aTYR PHARMA INC - 8-K, Current Report1
14.03.aTyr Pharma, Inc.: aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update127Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment in the second quarter of 2024. Company launches Individual Patient Expanded Access Program (EAP)...
► Artikel lesen
13.03.aTyr Pharma's Earnings Outlook1
28.02.aTyr Pharma, Inc.: aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results1
18.01.aTyr Pharma, Inc.: aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor2
13.11.23aTyr Pharma, Inc.: aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023240SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its...
► Artikel lesen
13.11.23aTyr Pharma files for $300M mixed-shelf offering4
10.11.23aTyr Pharma GAAP EPS of -$0.20, revenue of $0.3M2
09.11.23aTyr Pharma Inc reports results for the quarter ended in September - Earnings Summary4
09.11.23aTYR PHARMA INC - 10-Q, Quarterly Report1
09.11.23aTYR PHARMA INC - 8-K, Current Report1
09.11.23aTyr Pharma, Inc.: aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update152Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment early in the second quarter of 2024. Phase 2 EFZO-CONNECT study of efzofitimod in SSc-ILD initiated patient...
► Artikel lesen
09.05.23aTyr Pharma, Inc.: aTyr Pharma Announces First Quarter 2023 Results and Provides Corporate Update258Phase 3 EFZO-FIT study of efzofitimod in patients with pulmonary sarcoidosis currently enrolling in the U.S., Europe and Japan. Phase 2 proof-of-concept study of efzofitimod in patients with SSc-ILD...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1